Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Based on medical history, evidence of TG ≥ 150 mg/dL but ≤ 499 mg/dL~* Fasting levels at Screening of LDL-C ≥ 70 mg/dL OR non-HDL-C ≥ 100 mg/dL after at least 4 weeks of stable diet and stable optimal statin therapy~* Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL during Screening collected at two separate and consecutive visits and at least 7 days apart and not more than 17 days apart~* Willing to follow diet counseling and maintain a stable diet per Investigator judgment based on local standard of care~* Participants of childbearing potential must agree to use highly-effective contraception during the study and for at least 24 weeks from last dose of study medication~* Women of childbearing potential must have a negative pregnancy test and cannot be breastfeeding~* Women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to Day 1~* Men must not donate sperm during the study and for at least 24 weeks following the last dose of study medication~* Able and willing to provide written informed consent and to comply with study requirements~Exclusion Criteria:~* Current use or use within 365 days from Day 1 of any hepatocyte targeted siRNA or antisense oligonucleotide molecule~* Active pancreatitis within 12 weeks prior to Day 1~* Any planned bariatric surgery or similar procedures to induce weight loss from consent to end of study~* Acute coronary syndrome event within 24 weeks of Day 1~* Major surgery within 12 weeks of Day 1 or planned surgery during the study~* Planned coronary intervention (e.g., stent placement or heart bypass) during the study~* Uncontrolled hypertension~* Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV)~* Uncontrolled hypothyroidism or hyperthyroidism~* Hemorrhagic stroke within 24 weeks of Day 1~* History of bleeding diathesis or coagulopathy~* Current diagnosis of nephrotic syndrome~* Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or planned use during the study~* Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)~Note: additional inclusion/exclusion criteria may apply per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARO-ANG3 50 mg (Type: EXPERIMENTAL): Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
- ARO-ANG3 100 mg (Type: EXPERIMENTAL): Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
- ARO-ANG3 200 mg (Type: EXPERIMENTAL): Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
- Placebo (Type: PLACEBO_COMPARATOR): Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).